Actinium Pharmaceuticals presents preclinical data for ATNM-400 at SABCS.

Actinium Pharmaceuticals presented new preclinical data for ATNM-400, an antibody radioconjugate targeting breast cancer cells. The data shows that ATNM-400's target antigen is overexpressed in breast cancer and its expression is increased in breast cancer cells resistant to standard therapies. The Actinium-225 alpha-emitter payload induces irreversible DNA breaks and has potential for localized tumor killing with reduced off-target toxicity. The data supports further development of ATNM-400 as a monotherapy or combination therapy for multiple breast cancer subtypes.